Retatrutide: what the Phase 1, Phase 2, and preclinical literature has actually measured

The short version

Retatrutide is an experimental drug — not yet approved by the FDA or any other regulator — being studied for obesity and type 2 diabetes. It works by activating three hormone receptors at once (GIP, GLP-1, and glucagon), which together reduce hunger, improve blood sugar, and appear to increase the number of calories the body burns at rest. In a 48-week clinical trial, the highest dose studied produced an average 24.2% reduction in body weight among participants with obesity — a result larger than most approved medications in this class have shown. That said, it is still investigational: the large Phase 3 trials that will determine whether it receives approval are ongoing, and long-term safety data do not yet exist. This site is an independent reading of the published literature — not a clinic, not a vendor, and not a source of medical advice. What people report from research-use communities — including the downsides — is documented on the effects page.

What does retatrutide do

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide that simultaneously agonizes — that is, activates — three hormone receptors: the GLP-1 receptor (GLP-1R, which governs appetite and insulin release), the GIP receptor (GIPR, which modulates fat metabolism and insulin secretion), and the glucagon receptor (GCGR, which drives energy expenditure and hepatic fat breakdown). No previously approved drug has hit all three targets in one molecule at this potency profile.

In the discovery paper, Coskun et al. demonstrated balanced tri-receptor agonism and superior preclinical weight and metabolic effects versus single- or dual-agonist controls, providing the molecular rationale for the clinical program ^[7]. Cryo-EM structures subsequently resolved retatrutide's engagement of all three receptor complexes at high resolution, showing it is approximately 8.9× more potent at GIPR than native GIP while operating at 0.3× and 0.4× of native glucagon and GLP-1, respectively — a deliberate tuning designed to supply glucagon-driven energy expenditure without the hyperglycemia that full glucagon potency would produce ^[3].

The result of this retatrutide mechanism of action is a compound that does three things at once: suppresses appetite, controls blood glucose, and raises resting energy expenditure — mechanisms that work together rather than competing. Retatrutide research surveys these clinical findings in full.

Retatrutide results

The pivotal Phase 2 data come from two distinct trials published in 2023. In the obesity trial (Jastreboff et al., N Engl J Med), 338 adults with BMI ≥30 received once-weekly subcutaneous doses of 1, 4, 8, or 12 mg or placebo for 48 weeks. At the highest dose, mean body weight fell by 24.2% versus −2.1% with placebo — a difference of roughly 22 percentage points ^[1]. Gastrointestinal adverse events were dose-related and mostly mild-to-moderate; a dose-dependent heart-rate increase was observed, peaking around week 24 ^[1].

In the type 2 diabetes trial (Rosenstock et al., Lancet), 281 adults with T2D received stepwise dose escalation from 0.5 to 12 mg. At 24 weeks, 12 mg lowered HbA1c (glycated hemoglobin — an average blood-sugar marker) by −2.02% versus −0.01% with placebo; body weight fell 16.94% versus −3.00% by week 36 ^[2]. No severe hypoglycemia and no deaths were reported.

A substudy in participants with MASLD (metabolic dysfunction-associated steatotic liver disease — the current term for metabolic fatty liver) found that 12 mg reduced liver fat by −82.4% at 24 weeks, with 86% of participants normalizing liver-fat content to below 5% ^[5]. These hepatic findings, published in Nature Medicine, have drawn particular attention as MASLD affects a substantial fraction of adults with obesity.

Is retatrutide fda approved

Retatrutide is not FDA-approved. It is not approved by any regulatory body as of 2026. It is an investigational new drug in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. All efficacy and safety figures cited on this site come from clinical trials, not from approved labeling, because no approved label exists.

The distinction matters. Semaglutide and tirzepatide, two related GLP-1-class compounds, are approved drugs with labeled indications, post-marketing data, and regulated supply chains. Retatrutide has none of these. Any material described as retatrutide outside a clinical trial is an unregulated research substance of unverified identity and purity — not the compound studied in the trials whose data this site describes.

Phase 3 trials (TRIUMPH-1, -2, -3, and cardiovascular and kidney outcome studies) are ongoing. No approval timeline has been publicly confirmed.

Retatrutide availability

Retatrutide is not commercially available. It is not sold by prescription, available at compounding pharmacies, or stocked in retail channels. The only legitimate setting in which a person receives authentic retatrutide today is enrollment in one of Eli Lilly's ongoing clinical trials.

A gray market for research-labeled material exists. The FDA issued more than 50 warning letters to retatrutide vendors in 2025 citing Federal Food, Drug, and Cosmetic Act violations. Gray-market products cannot be confirmed to contain authentic retatrutide at stated concentration; independent analyses of similar gray-market peptides have found incorrect amino acid sequences, racemized residues, or entirely different compounds. When will retatrutide be available as an approved product depends on Phase 3 results and regulatory review — no timeline has been publicly committed to by the developer.